Avapritinib
Augtyro is a prescription brand-name medication classified as a next-generation tyrosine kinase inhibitor (TKI). It is specifically designed to target and treat cancers driven by ROS1 or NTRK gene alterations. This medication is used in adults with advanced or metastatic cancers that have these specific genetic mutations.
Augtyro is a targeted cancer therapy for adults with ROS1-positive lung cancer or NTRK fusion-positive solid tumors.
Key facts at a glance
- RxNorm
- 2670650
- Generic
- Augtyro
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Augtyro is indicated for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), as well as adult patients with locally advanced or metastatic solid tumors that have an NTRK gene fusion and have progressed following treatment or have no satisfactory alternative options.
Augtyro contains the active ingredient repotrectinib, which works as a next-generation tyrosine kinase inhibitor. It targets and blocks the activity of ROS1 and TRK (from NTRK gene fusions) proteins, which are abnormal forms of tyrosine kinases that drive cancer cell growth and proliferation. By inhibiting these targets, the medication helps slow or stop cancer cell growth.
Augtyro may cause serious side effects including neurological effects (dizziness, balance problems, tingling sensations), liver problems, and potential harm to an unborn baby. Patients should avoid driving or operating machinery if they experience dizziness. The medication may interact with other drugs, and patients should inform their healthcare provider of all medications. Treatment should be supervised by an oncologist experienced with targeted cancer therapies.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 2, 2026. · Read our editorial policy